Home   /  Find a Trial  /  See All TrialsHELP /  AYUDA /  求助 : (415) 476-5777 | Click to print page Print
 

See All Trials

QuickViews

Match by Tumor Type:

Newly Diagnosed (Stage I-III)
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)
Inflammatory Breast Cancer
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)

View by Trial Type:

Treatment:

 

Non-Treatment:

see All Trials

Sort by zip code:  

 

Share

Facebook
Twitter
Twitter

 
Screening

MRI in Women Who are Healthy, High Risk or Have Breast Cancer

Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants (NCT00474604)

Summary

Magnetic Resonance Imaging (MRI) is a sensitive method for detecting breast cancer that has been useful in evaluating women who are at high risk for breast cancer. In addition to standard MRI, three new methods are currently being studied: Magnetic Resonance Spectroscopy (MRS) provides information about the chemical make-up of the tumor tissue, Dynamic Contrast-Enhanced MRI (DCE-MRI) uses faster imaging and a contrast material to provide information about the tumor's blood vessels, and Diffusion-weighted MRI (DW-MRI) creates images that provide information about the tumor tissue. This study will compare how well these three different MRI methods find and characterize breast tumors, compared to standard MRI. Women who have been recently diagnosed or suspected to have breast cancer, as well as healthy volunteers, are eligible for this study.

Information About Mammography Screening for Women Age 75 and Older

Randomized Trial of a Mammography Decision Aid for Women Aged 75 and Older (NCT02198690)

Summary

It is not known whether the benefits of mammography screening outweigh the risks in women age 75 and older. To improve older women's understanding of the benefits and risks of mammography screening, researchers have developed a pamphlet that provides information about mammography specifically for this age group. This study is investigating whether the pamphlet improves older women's decision-making about mammography screening. To be eligible, women must be between the ages of 75 and 89.

Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography

Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography for Supplemental Breast Cancer Screening (NCT02310698)

Summary

Researchers are trying to identify the best imaging technologies to use along with mammography. Breast ultrasound is sometimes used as an additional test. Studies have shown that it can detect cancers that are not seen on regular mammography. Contrast Enhanced Digital Mammography (CEDM) is an FDA-approved form of mammography. It uses a dye injected into a vein to "highlight" areas of increased blood supply, which may indicate the presence of cancer cells. CEDM has been shown to detect cancer cells that are not seen on a regular mammogram. This study is comparing the effectiveness of CEDM and breast ultrasound when used along with mammography. To be eligible, a woman must be scheduled to receive contrast enhanced digital mammography alone or with whole breast screening ultrasound or full field digital mammography on the same day or within 30 days of one another.

A Blood Test for Circulating Tumor Cells for Cancer Screening

Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma (NCT01322750)

Summary

Scientists are trying to identify effective new techniques for breast cancer screening. Researchers now believe that breast cancer cells can leave the breast and move through the blood stream to other parts of the body before the tumor is even clinically detectable. Reliable and accurate detection of these circulating tumor cells (CTCs) is now possible with a simple blood test. The goal of this research is see whether a blood test for CTCs could provide a simple, reliable, cost-effective form of breast cancer screening. The aim of this specific study is to evaluate whether individuals with CTCs and no other signs of malignancy have clinically undetectable breast cancer. To be eligible, participants must be military health care beneficiaries.

CT Scan vs. Mammogram for Breast Cancer Detection

Evaluation of Breast CT (NCT00584233)

Summary

There are ongoing efforts towards improving methods for breast cancer detection and diagnosis. This trial will study the comparison between digital mammograms (obtained through routine clinical screening) with the images created by the breast CT scanner using contrast agent injection, for breast cancer detection. Breast CT (computed tomography) uses 3D imaging to show the breast in its real three dimensional shape. The use of contrast agent injection allows researchers to view images of both the anatomy and the blood flow in the breast. Women who have been identified as having suspicious lesions on their mammograms and who are scheduled for breast biopsy are eligible to participate in this trial.
This is a Phase II trial

Breast Cancer Screening with Ultrasound and Mammography

Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Screening Mammography, Including Cost Comparisons (NCT00649337)

Summary

Abnormalities can be more difficult to detect on a mammogram when women have dense breast tissue. Ultrasound imaging is a noninvasive medical test that produces a picture of the internal structures of the breast and is used to complement other screening tests, such as mammography. SonoCine is an innovative exam that uses a standard ultrasound machine to take a video of the entire breast. The purpose of this study is to determine whether adding whole breast ultrasound with SonoCine to annual screening mammography is more effective in women with dense breast tissue than mammography alone. To be eligible, participants must not have had a screening mammogram within 10 months of study entry or have been diagnosed with breast cancer within the last year.

Using DWI with MRI for Breast Cancer Detection

A MULTI-CENTER STUDY EVALUATING THE UTILITY OF DIFFUSION WEIGHTED IMAGING FOR DETECTION AND DIAGNOSIS OF BREAST CANCER (NCT02022579)

Summary

Magnetic resonance imaging (MRI) is currently used to screen high-risk women. Diffusion-weighted imaging (DWI) calculates a measure of how water moves through tissue. Because water moves at different rates through healthy breast tissue and cancerous breast tissue, incorporating DWI into conventional breast MRI may decrease false positives and reduce preventable biopsies. In this study, researchers will investigate the accuracy of MRI combined with DWI in women with breast tumors that were identified on MRI. The DWI will be done at the time of the MRI, adding an additional two minutes to the MRI procedure.